Advertisement

Search Results

Advertisement



Your search for The,The matches 33799 pages

Showing 401 - 450


hepatobiliary cancer
cardio-oncology

Do Nonstatin Cholesterol-Lowering Drugs Influence the Risk of Hepatic Cancer?

Investigators examined whether nonstatin cholesterol-lowering drugs may affect the risk of hepatic cancer, according to a recent study published by Zamani et al in Cancer. Background Hepatic cancer is the sixth most common cancer type across the world and the third leading cause of cancer-related...

breast cancer

Endocrine-Resistant Metastatic Breast Cancer

This is Part 3 of Next-Generation Therapies for Metastatic Hormone Receptor–Positive Breast Cancer: Where Are We Headed?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Virginia Kaklamani, William Gradishar, and Komal Jhaveri...

breast cancer

PIK3CA-Mutated Metastatic Breast Cancer

This is Part 2 of Next-Generation Therapies for Metastatic HR-Positive Breast Cancer: Where Are We Headed?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Virginia Kaklamani, William Gradishar, and Komal Jhaveri discuss the...

breast cancer

ESR1-Mutated Metastatic Breast Cancer

This is Part 1 of Next-Generation Therapies for Metastatic HR-Positive Breast Cancer: Where Are We Headed?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Virginia Kaklamani, William Gradishar, and Komal Jhaveri discuss the...

lung cancer
immunotherapy

Advanced NSCLC: Association of Intratumoral Escherichia With Overall Survival

In a study reported in the Journal of Clinical Oncology, Arielle Elkrief, MD, and colleagues found that detection of intratumoral Escherichia was associated with improved overall survival in patients with advanced non–small cell lung cancer (NSCLC) receiving single-agent immune checkpoint inhibitor ...

global cancer care

Making a Difference in Global Oncology

“Making a difference in global oncology means framing positive system changes. To me, Dr. Khalid El Bairi is among the global cancer researchers I know who so far has made the largest achievements. “Since the very first interaction with Khalid, what I have captured is passion for the community he...

global cancer care

Cancer Research and Care Beyond Borders for Global Oncologist Dario Trapani, MD

In this installment of The ASCO Post’s Living a Full Life series, I interviewed Dario Trapani, MD, a medical oncologist at the European Institute of Oncology, Milan and Assistant Professor at the Department of Oncology and Haemato-Oncology of the University of Milan, in Italy. Dr. Trapani is a...

skin cancer
immunotherapy

Key Immune Cells for Combating Aggressive Merkel Cell Carcinoma Uncovered

Researchers may have uncovered why some patients with Merkel cell carcinoma do not respond to immune checkpoint blockade therapy, according to a recent study published by Reinstein et al in Cancer Discovery. Background Merkel cell carcinoma—a rare but highly aggressive type of skin cancer—is known...

gastroesophageal cancer
hepatobiliary cancer
immunotherapy
issues in oncology

Fecal Microbiota Transplant May Help Patients With Gastrointestinal Cancers Overcome Immunotherapy Resistance

Fecal microbiota transplants may improve the effectiveness of immunotherapy in patients with gastrointestinal cancers, according to a recent study published by Kim et al in Cell Host & Microbe. Background Although immune checkpoint inhibitors have revolutionized cancer treatment, many patients...

breast cancer

Sara A. Hurvitz, MD, FACP, on New Therapeutic Strategies for HER2-Positive Metastatic Disease Including Brain Metastases

Sara A. Hurvitz, MD, FACP, of Fred Hutch Cancer Center, discusses her presentation on new therapeutic strategies for HER2-positive metastatic disease including brain metastases. Dr. Hurvitz is Senior Vice President and Director, Clinical Research Division, Fred Hutch Cancer Center, and Professor,...

hematologic malignancies
supportive care

Effect of Posttransplantation Cyclophosphamide-Based GVHD Prophylaxis on Patients With Hematologic Malignancies

In an analysis reported in the Journal of Clinical Oncology, Shaffer et al found that use of post–allogeneic hematopoietic cell transplantation (HCT) cyclophosphamide (PTCy)-based graft-vs-host disease (GVHD) prophylaxis resulted in comparable overall survival and GVHD-free, relapse-free survival...

leukemia

MRD-Negative ALL: Addition of Blinatumomab to Consolidation Chemotherapy

In the phase III ECOG-ACRIN E1910 trial reported in The New England Journal of Medicine, Mark R. Litzow, MD, and colleagues found that the addition of blinatumomab to consolidation chemotherapy improved overall survival among adult patients with BCR-ABL fusion–negative B-cell precursor acute...

prostate cancer

Baseline Bone Pain and Survival in Newly Diagnosed Prostate Cancer

In an analysis from the SWOG-1216 trial reported in JAMA Network Open, Gebrael et al found that the presence of bone pain at diagnosis was associated with poorer progression-free and overall survival in patients with newly diagnosed metastatic hormone-sensitive prostate cancer. Study Details In the ...

colorectal cancer

Guardant Health’s Shield Blood Test Approved by the FDA as a Primary Screening Option for Colorectal Cancer

On July 29, the U.S. Food and Drug Administration (FDA) approved Guardant Health’s Shield blood test for colorectal cancer screening in adults aged 45 years and older who are at average risk for the disease. It is the first blood test to be approved by the FDA as a primary screening option for...

prostate cancer
issues in oncology

Is Lower-Dose Radiopharmaceutical Therapy Effective in Advanced Prostate Cancer?

Treatment with de-escalated actinium (Ac)-225–prostate-specific membrane antigen (PSMA)-617 or a combination of lutetium (Lu)-177/Ac-225–PSMA-617 resulted in similar median overall survival and prostate-specific antigen (PSA) response rates and better tolerance among patients with advanced-stage...

breast cancer
gynecologic cancers
issues in oncology

Risk of Breast Cancer May Be Lower Within First 10 Years Following Ovarian Cancer Diagnosis

Patients with BRCA1- or BRCA2-mutated ovarian cancer may have a lower risk of developing breast cancer following treatment, according to a recent study published by Evans et al in Genetics in Medicine. Background Previous research has estimated that the risk of developing breast cancer by the age...

breast cancer

Does Bilateral Mastectomy for Unilateral Breast Cancer Impact Mortality?

The results of a contemporary U.S. population–based cohort study published by Giannakeas et al in JAMA Oncology revealed that patients with unilateral breast cancer had an increased risk of breast cancer–related death after developing contralateral disease. Although the findings also showed a...

prostate cancer
cardio-oncology

Patients With Prostate Cancer: Social Factors May Be Tied to Racial Disparities in Cardiovascular Outcomes

Based on the results of a retrospective cohort study published by Demissei et al in JACC: CardioOncology, Black patients with prostate cancer who received systemic androgen-deprivation therapy (ADT) seemed to have a significantly greater likelihood of experiencing adverse cardiovascular disease...

breast cancer
supportive care

Update on Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) Trial in Patients With Breast Cancer

Guest Editor’s Note: Chemotherapy and its side effects can lead to decreased physical activity and poor diet quality, resulting in unfavorable changes in physical functioning and quality of life. However, adopting healthy behaviors during cancer treatments can be challenging because of physical,...

solid tumors

Triplet as Initial Salvage Treatment for Advanced Germ Cell Tumors: Long-Term Outcomes

In a long-term analysis reported in the Journal of Clinical Oncology, Gleeson et al found that initial salvage treatment for germ cell tumors with paclitaxel, ifosfamide, and cisplatin (TIP) was associated with positive long-term outcomes in both favorable- and unfavorable-risk disease. Study...

cns cancers
issues in oncology

New Study Highlights Improvements in Treating Pediatric Patients With Retinoblastoma

The advancement of retinoblastoma treatment over the past 15 years may have resulted in a higher likelihood of vision preservation without compromising survival, according to a recent study presented by Kocharian et al at the Society of NeuroInterventional Surgery (SNIS) Annual Meeting 2024 and...

issues in oncology
hematologic malignancies
leukemia
lymphoma
bladder cancer

Cancer Risk From Exposure to Pesticides May Be Comparable to Risk From Smoking, Study Finds

Agricultural pesticides may carry a similar risk as smoking for some types of cancers, according to a recent study published by Gerken et al in Frontiers in Cancer Control and Society.   Background In modern agriculture practices, pesticides are essential to ensure high enough crop yields and food...

hepatobiliary cancer

Localized Hepatocellular Carcinoma

This is Part 3 of Immunotherapy Strategies for Hepatobiliary Cancers, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Rachna T. Shroff, Nilo Azad, and Anthony B. El-Khoueiry discuss the management of localized hepatocellular...

hepatobiliary cancer

Advanced Cholangiocarcinoma

This is Part 2 of Immunotherapy Strategies for Hepatobiliary Cancers, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Rachna T. Shroff, Nilo Azad, and Anthony B. El-Khoueiry discuss the management of advanced...

hepatobiliary cancer

Advanced Unresectable Hepatocellular Carcinoma

This is Part 1 of Immunotherapy Strategies for Hepatobiliary Cancers, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Rachna T. Shroff, Nilo Azad, and Anthony B. El-Khoueiry discuss the management of advanced unresectable...

Introducing ‘Conexiant’

The publisher and editorial staff of The ASCO Post are happy to share an exciting announcement. While our company was formerly known as Harborside, powered by BroadcastMed, earlier this summer we announced a new name and platform for our business, Conexiant. Importantly, we continue our essential...

Cancer and Fatherhood: A Story of Personal Power in the Face of a Mortal Disease

Iron Dad: A Cancer Survivor’s Story of Discovering Strength, Life, and Love Through Fatherhood by Paul Weigel is an inspiring and deeply moving memoir that transcends the traditional boundaries of parenthood and personal transformation. This story begins with a sense of discontent and a desire for...

lymphoma

Addition of Ibrutinib to Immunochemotherapy and ASCT Improves Survival in Mantle Cell Lymphoma

As reported in The Lancet by Martin Dreyling, MD, PhD, of Ludwig Maximilian University Hospital Munich, and colleagues, results in the European Mantle Cell Lymphoma Network phase III TRIANGLE trial indicate that the addition of ibrutinib to immunochemotherapy and autologous stem cell...

lung cancer

Phase II Study Shows Activity for Novel Targeted Agent in KRAS G12C–Mutated NSCLC

The oral KRAS G12C inhibitor glecirasib has emerged as a therapeutic option for previously treated KRAS G12C–mutated non–small cell lung cancer (NSCLC). It may potentially improve efficacy and tolerability compared with current U.S. Food and Drug Administration–approved agents, according to data...

supportive care

Updated ASCO Guidance on Cancer-Related Fatigue Expands Patient Options for Interventions

A new update to the ASCO guideline on managing cancer-related fatigue recommends that health care providers urge their patients to exercise, as well as use cognitive-behavioral therapy and mindfulness-based programs to help prevent and treat this prevalent symptom.1 It is estimated that between 30% ...

lung cancer

Amivantamab-vmjw in NSCLC With EGFR Exon 20 Insertion Mutations

On March 1, 2024, amivantamab-­vmjw (Rybrevant) was approved for use with ­carboplatin and pemetrexed for first-line treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by a U.S. Food and Drug Administration...

lymphoma

Triplet Combination Improves Survival in Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Third-Line Setting

The anti-CD30 antibody-drug conjugate brentuximab vedotin is a standard of care for certain types of lymphomas, including classical Hodgkin lymphoma in combination with multiagent chemotherapy. Brentuximab vedotin has also shown efficacy and safety in combination with lenalidomide and rituximab in...

gastroesophageal cancer

ESOPEC Trial: FLOT Protocol Proves Superior to CROSS Regimen in Locally Advanced Esophageal Cancer

The phase III ESOPEC trial, conducted in Germany, compared two regimens for locally advanced esophageal cancer and found an overall survival benefit with the perioperative FLOT protocol over the neoadjuvant chemoradiotherapy CROSS regimen. The results were presented during the Plenary Session of...

lung cancer

Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment: Meeting Highlights

The international meeting in Madrid of the newly formed Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment (AGILE) was held in May 2024. This diverse forum included health-care professionals, public health leaders, industry representatives, and patient...

issues in oncology

Failure to Diagnose and Statutes of Limitations: Lavern’s Law and Its Implications for Oncology

When health-care providers, including oncologists, fail to promptly diagnose a medical condition or communicate their diagnosis to their patients, it can have devastating consequences for those patients. In such cases, patients may seek legal recourse through medical malpractice lawsuits, creating...

multiple myeloma

Two Phase III Trials Report Benefit With Isatuximab-Based Regimens in Newly Diagnosed Multiple Myeloma

In newly diagnosed, transplant-ineligible patients with multiple myeloma, treatment with the anti-CD38 monoclonal antibody isatuximab plus bortezomib, lenalidomide, and dexamethasone (VRd) led to a 40% reduction in the risk of disease progression or death and “deep and sustained responses,” almost...

breast cancer

RSClin Tool and Risk for Late Distant Recurrence in Breast Cancer

In a study reported in NEJM Evidence, Joseph A. Sparano, MD, and colleagues found that a risk score integrating the 21-gene recurrence score (RS) with clinicopathologic factors—the RSClin tool—performed well in predicting risk of late distant recurrence in patients with breast cancer. Study...

colorectal cancer

Neoadjuvant Camrelizumab Plus Apatinib in Locally Advanced Colorectal Cancer

In a Chinese phase II study (NEOCAP) reported in The Lancet Oncology, Yu et al found that neoadjuvant camrelizumab plus apatinib produced promising complete response rates in patients with locally advanced microsatellite instability–high or mismatch repair–deficient colorectal cancer. Study ...

multiple myeloma
immunotherapy

Multiple Myeloma: Using Absolute Lymphocyte Count to Predict Outcomes After CAR T-Cell Therapy

A simple blood test that measures lymphocyte counts may predict whether patients with relapsed multiple myeloma are going to respond well to chimeric antigen receptor (CAR) T-cell immunotherapy, according to research published by Saldarriaga et al in Blood Advances. The study found that patients...

lymphoma
immunotherapy
issues in oncology

Shortening FDA-Mandated CAR T-Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL

Two hallmark toxicities of chimeric antigen receptor (CAR) T-cell therapy may be rare after 2 weeks following infusion in patients with diffuse large B-cell lymphoma (DLBCL), supporting a shorter, more flexible toxicity monitoring period., according to a recent study published by Ahmed et al in...

colorectal cancer
issues in oncology

Eliminating Racial Disparities in Colorectal Cancer Screening

Eliminating racial disparities in colorectal cancer testing may reduce the rate of colorectal cancer incidence and mortality among Black patients in the United States, according to a recent study published by Alagoz et al in the Journal of the National Cancer Institute. Background Although both the ...

pancreatic cancer
pain management

Pancreatic Cancer: Celiac Plexus Radiosurgery for Retroperitoneal Pain Syndrome

In a phase II study reported in The Lancet Oncology, Lawrence et al found that celiac plexus radiosurgery showed promise in the alleviation of retroperitoneal pain syndrome in patients with pancreatic cancer or other tumors involving the celiac axis. Study Details Between January 2018 and December...

hepatobiliary cancer
immunotherapy

Immunotherapy in Unresectable HCC With Child-Pugh Class B Dysfunction

In a retrospective study reported in JAMA Oncology, Fulgenzi et al found evidence that immune checkpoint inhibitor (ICI)-based treatment may improve survival vs best supportive care as first-line therapy in patients with unresectable hepatocellular carcinoma and Child-Pugh class B (CP-B) liver...

breast cancer
supportive care

Kristin Rojas, MD, FACS, on Improving Sexual Health During Breast Cancer Treatment

Kristin Rojas, MD, FACS, of the University of Miami, shares key points from her discussion on improving sexual health during breast cancer treatment. Dr. Rojas is an Associate Professor of Surgery in the DeWitt Daughtry Family Department of Surgery, Division of Surgery, Miller School of Medicine at ...

breast cancer

Joseph A. Sparano, MD, FACP, on Premenopausal HR-positive Early Breast Cancer: What to Do Outside the OFSET Trial?

Joseph A. Sparano, MD, FACP, of Icahn School of Medicine at Mount Sinai, discusses his presentation on premenopausal patients with hormone receptor–positive early breast cancer. Dr. Sparano is the Ezra M. Greenspan, MD, Professor in Clinical Cancer Therapeutics, Chief of the Division of Hematology...

cardio-oncology

Does Neighborhood Walkability Impact the Burden of Cardiovascular Risk Factors in Patients With Cancer?

The results of a cross-sectional study reported in JACC: CardioOncology by Nwana et al revealed a significant association between the extent to which a neighborhood facilitates walking and the burden of modifiable cardiovascular risk factors among patients with a history of cancer. “[The findings...

leukemia

Novel Target Identified for Treating HTLV-1–Associated Diseases

Blocking the tyrosine kinase KDR could lead to cell death caused by the degradation of the TAX viral protein, thereby treating diseases associated with human T-cell leukemia virus type 1 (HTLV-1), according to a recent study published by Mohanty et al in Nature Communications. Background HTLV-1 is...

solid tumors
issues in oncology

AACR, ASA, FDA Outline Considerations for Overall Survival Analyses in Clinical Trials

Experts from the American Association for Cancer Research (AACR), American Statistical Association (ASA), and U.S. Food and Drug Administration (FDA) have outlined considerations for clinical trial designs to enhance the collection and analysis of overall survival data in the context of modern-day...

breast cancer

Paolo Tarantino, MD, on the Current and Future Landscape of Antibody-Drug Conjugates

Paolo Tarantino, MD, of Dana-Farber Cancer Institute and Harvard Medical School, shares key points from his discussion on the current and future landscape of antibody-drug conjugates. Dr. Tarantino is an Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute and...

breast cancer

Aditya Bardia, MD, MPH, FASCO, on Novel Therapies Targeting the Estrogen Receptor

Aditya Bardia, MD, MPH, FASCO, of UCLA Health/Jonsson Comprehensive Cancer Center, shares key points from his discussion on novel therapies targeting the estrogen receptor. Dr. Bardia is Professor, Department of Medicine, Division of Hematology/Oncology, and Director of Translational Research...

Advertisement

Advertisement




Advertisement